![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EPEIUS BIOTECHNOLOGIES RECEIVES ACCELERATED APPROVAL FOR REXIN-G IN THE PHILIPPINES
EPEIUS BIOTECHNOLOGIES RECEIVES ACCELERATED APPROVAL FOR REXIN-G IN THE PHILIPPINES
Epeius Biotechnologies announced the Bureau of Food and Drugs (BFAD), the Philippine drug regulatory body, has granted Epeius Biotechnologies accelerated approval for the company's lead clinical product, Rexin-G for the treatment of all solid tumors. This approval closely follows the recent granting of an Expanded Access Program by BFAD to Epeius for Rexin-G, which extended Rexin-G clinical applications to patients with solid tumors, including but not limited to pancreatic cancer. Drug Newswire (http://www.drugnewswire.com/4685/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct